Lactobacillus Johnsonii Supplementation in Adults With T1D

NCT03961347 | Active Not Recruiting Phase 2 DMC FDA Drug

• 3 other identifiers: IRB201901428 -NOCR225021R01DK121130-01A1
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 1

Brief Summary

While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.

Conditions

Type 1 Diabetes (T1D)

Keywords

probiotics; genetics

Outcome Measures

Primary Outcomes (3)

• Safety will be evaluated according to complete blood count (CBC) and complete comprehensive metabolic panel (CMP)

  CBC and CMP will be evaluated at four different time points during study: 1st measure will be at screening visit and before starting intervention (visit 1/week -4, baseline period), 2nd measure will be after 12 weeks after starting intervention (visit 2/ week 12), 3rd measure will be after the 24 weeks of intervention (visit 3/ week 24) and the 4th measure will be 24 weeks later, end of washout period (visit 4/week 48). Values should be within the normal range except for glucose.

  52 weeks

• Tolerance will be evaluated according to their responses on weekly questionnaires

  The weekly questionnaire will ask participants to respond to questions regarding their gastrointestinal health (bowel movement frequency, gastrointestinal and other symptoms (i.e., constipation, diarrhea, stomach pain) and general wellness (if you consumed an antibiotic, visited a doctor, etc.). The questionnaires follow a scale from 1-7, 1 = No discomfort at all, 7 = Very severe discomfort.

  52 weeks

• Adverse Event and/or Serious Adverse Event

  Adverse Event and/or Serious Adverse Event will be recorded daily by parents and notified to investigator within 24 hrs., in particular gastro-intestinal symptoms, fever and rashes.

  24 weeks

Study Arms (2)

Probiotic Group

ACTIVE COMPARATOR

The probiotic group will receive a daily capsule with Lactobacillus johnsonii N6.2 1x109 Colony Forming Units (CFUs). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.

Drug: L. johnsonii Probiotic

Placebo Group

PLACEBO COMPARATOR

The placebo group will receive a capsule daily with dried skim milk (vehicle of the probiotic). Participants will consume one capsule (treatment or placebo) daily for 24 weeks.

Drug: Placebo Capsule

Interventions

L. johnsonii Probiotic DRUG

Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.

Probiotic Group

Placebo Capsule DRUG

Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.

Placebo Group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Have confirmed T1D by physician diagnosis
• Have normal values at screening for CBC and complete metabolic profiles (with the exception of fasting glucose and HbA1c).
• Are able to swallow a capsule.
• Are willing to complete weekly online questionnaires.\*
• Are willing to consume a probiotic or placebo capsule daily for 24 weeks.
• Are willing to provide stool samples throughout the study.
• Are willing to provide blood samples throughout the study.
• Are willing to take three 2-hour Mixed-Meal Tolerance Tests (MMTTs).
• Are able to access a computer with Internet throughout the study.\*
• Note: Going into the study, we want the participants to have daily internet access. However, if this changes once they are in the study, we will provide paper copies of the questionnaires.

You may not qualify if:

• Have had or are currently being treated for any diseases or illnesses such as gastrointestinal disease (gastric ulcers, Crohn's, ulcerative colitis, etc.).
• Have chronic disease kidney disease.
• Have had or are currently being treated for other immune-compromising diseases or conditions (HIV, AIDS, hepatitis, cancer, leukemia, transplant patient, Lupus, DiGeorge syndrome, selective deficiency of Immunoglobulin A (IgA), Bruton's disease etc.).
• Have an underlying structural heart disease.
• Currently live with an immunocompromised person.
• Are currently taking medications for constipation and/or diarrhea.
• Have taken antibiotics within the past 2 weeks prior to randomization.
• Are currently taking a probiotic supplement and are unwilling to discontinue it a minimum of 2 weeks prior to the study start.
• Are a current smoker.
• Are currently pregnant or lactating or a female who plans to become pregnant in the next 6 months.
• Have a known allergy to milk or milk protein.

Sponsors & Collaborators

• University of Florida: lead
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): collaborator

Study Sites (1)

UF Clinical Research Center

Gainesville, Florida, 32610, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Autoimmune Diseases; Immune System Diseases

Study Officials

• Michael Haller

  University of Florida

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: A randomized, double-blinded, placebo-controlled clinical trial will be carried out in subjects between 18-45 years old with T1D.

Study Record Dates

• First Submitted: May 22, 2019
• First Posted: May 23, 2019
• Study Start: February 1, 2020
• Primary Completion: March 18, 2026
• Study Completion: March 18, 2026
• Last Updated: March 12, 2026

Record last verified: 2025-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)